 |
|
Steve Furlong is an optical physicist and patent engineer with over 25 years of experience designing custom optics and optical sensor systems for military, communications and medical applications. Steve's technical specialties include:
- Computer aided optical design and analysis (via ZEMAX, Code V, Beam 4, OptiCad, and MathCad) of both imaging and non-imaging micro optical components spanning the spectral range from the ultraviolet to the near infrared
- Custom design of fiber optic and integrated optic components including 3 and 4 port fiber optic couplers, optical phase and single side-band frequency modulators, and active polarization maintaining servo systems utilizing birefringent optical elements
- Design and development of miniaturized absorption and fluorescence spectrometers (both dispersive and scanning) sufficiently small to fit in "cell phone" dimensions
- Design of fiber optic immuno-assay and blood gas analysis systems performing fluorescence spectroscopy on whole blood
- Design of airborne laser target designator systems, optical weapons, and all-optical guidance systems (fiber optic gyroscopes and accelerometers) for tactical and ballistic missiles
Prior to joining Altera Law Group, Steve was the Vice President and Chief Technology Officer of the LifeSpex Corporation developing breakthrough optical imaging technology for the early detection of cancer. In addition, Steve was the Vice President of Research & Development at Instrumentation Metrics Inc., a medical device group developing optical techniques for the non-invasive measurement of blood glucose for diabetes management. Also in the medical area, Steve was formerly the Director of Optical Technology at Optical Sensors Incorporated, which developed patient-attached, on-demand Arterial Blood Gas monitoring systems.
Early in Steve's career he designed military optical weapons and guidance systems at the Martin Marietta Aerospace Corporation where he was the first recipient of their Corporate Fellowship for graduate studies in lasers and electro-optics. In addition, Steve later designed military systems at the Litton Industries Guidance & Control Group in California.
Steve has authored numerous technical publications and has given scientific presentations both in Europe and Asia, as well as at many major U.S. conferences. Steve has been named as inventor on four U.S. patents and five pending U.S. patent applications.
Powell Goldstein has formed a strategic alliance with the Altera Law Group to enhance our abilities to serve our clients' specialized intellectual property needs. Our alliance helps clients maximize the value of their intellectual property resources, whether patent, trademark, trade-secret, copyright or related areas of law, by combining them into an effective strategy. To learn more about how our strategic alliance with Altera can help you, we invite you to visit Altera's web site: http://www.alteralaw.com/index.htm.
|
|
Education |
| |
| Ph.D., Physics, Columbia University, New York City
|  | | M.S., Electrical Engineering, University of Central Florida
|  | | B.S., Physics, University of West Florida |  |
|
Memberships |
| |
| Sigma Pi Sigma (Society of Honors Graduates in Physics) |  |
|
Publications |
| |
Ph.D. Dissertation: "Integrated & Micro-Optic Components for Optical Sensor Systems."
M.S. Thesis: "On the Theory and Experimental Results of a Sensitive Fiber Optic Laser Accelerometer."
U.S. Patent 6,865,407 (Inventor), Calibration Technique For Non-Invasive Medical Devices.
U.S. Patent 5,714,121 (Inventor), Optical Carbon Dioxide Sensor & Methods of Manufacture.
U.S. Patent 5,672,515 (Inventor), Simultaneous Dual Excitation Single Emission Fluorescent Sensing Method For pH & pCO2.
U.S. Patent 4,717,225 (Inventor), Form Polarizing Fibers & Methods of Manufacturing.
"Feasibility study of a plastic evanescent wave optical sensors," presented at European Conference On Optical Sensors, Graz, Austria.
"Performance & use of fiber optic blood gas sensors," presented at SPIE Conference on Biomedical Fiber Optic Sensors, Los Angeles.
"Clinical Trial Update in Detecting In-Situ Cervical Cancer via Induced Optical Fluorescence," presented at European Biomedical Conference, Paris, France.
|
|
| |
| |
|
|